Contributions
Abstract: PB1824
Type: Publication Only
Background
Health-related quality-of-life (HRQoL) profile is now recognized as an important component in the management of Chronic myeloid leukemia (CML).
Aims
To explore the HRQoL profiles of patients with CML in the chronic phase (CP) who were treated with front-line imatinib or nilotinib, in order to assess the relationship between early response and HRQoL outcomes.
Methods
A prospective, longitudinal, single center study was conducted to assess the response to treatment with imatinib or nilotinib and the HRQoL profile of patients who were newly diagnosed with CML-CP enrolled into ENESTchina study. Responses based on molecular and cytogenetic outcomes were measured according to the European LeukemiaNet recommendations, and patient-reported HRQoL profile was measured by the SF-36 health survey.
Results
Fifty-nine patients were randomly assigned to receive imatinib (n = 31) or nilotinib (n = 28). In multivariate analysis, the use of nilotinib was identified as an independent factor affecting the achievement of optimal response at 6 months (OR = 3.9, 95% CI, 1.0-14.9; P =0.043) and 12 months (OR = 5.6, 95% CI, 1.7-17.9; P =0.004). With a median follow-up of 60 months, the probabilities of failure-free survival (all P values < 0.001) and progression-free survival (all P values < 0.05) at 5 years were significantly higher in patients who achieved optimal response at 3, 6, or 12 months than those who achieved non-optimal response (warning or failure), and overall survival rate at 5 years was significantly higher in those who achieved optimal response at 12 months (P =0.047). Achieving optimal response at 12 months was associated with better role limitations due to physical health problems (P =0.0019) and role limitations due to emotional problems (P =0.0110) and was the sole factor associated with significantly improving physical component summary over time (P =0.0160). In addition, achieving optimal response at 6 months had a tendency of high physical functioning (P =0.0674), social functioning (P =0.0571), and role limitations due to emotional problems (P =0.0916) scores. Age <40 years, female gender, and higher education level were also associated with better HRQoL subscales.
Conclusion
Session topic: 8. Chronic myeloid leukemia - Clinical
Keyword(s): Tyrosine kinase inhibitor, Quality of Life, Chronic myeloid leukemia
Abstract: PB1824
Type: Publication Only
Background
Health-related quality-of-life (HRQoL) profile is now recognized as an important component in the management of Chronic myeloid leukemia (CML).
Aims
To explore the HRQoL profiles of patients with CML in the chronic phase (CP) who were treated with front-line imatinib or nilotinib, in order to assess the relationship between early response and HRQoL outcomes.
Methods
A prospective, longitudinal, single center study was conducted to assess the response to treatment with imatinib or nilotinib and the HRQoL profile of patients who were newly diagnosed with CML-CP enrolled into ENESTchina study. Responses based on molecular and cytogenetic outcomes were measured according to the European LeukemiaNet recommendations, and patient-reported HRQoL profile was measured by the SF-36 health survey.
Results
Fifty-nine patients were randomly assigned to receive imatinib (n = 31) or nilotinib (n = 28). In multivariate analysis, the use of nilotinib was identified as an independent factor affecting the achievement of optimal response at 6 months (OR = 3.9, 95% CI, 1.0-14.9; P =0.043) and 12 months (OR = 5.6, 95% CI, 1.7-17.9; P =0.004). With a median follow-up of 60 months, the probabilities of failure-free survival (all P values < 0.001) and progression-free survival (all P values < 0.05) at 5 years were significantly higher in patients who achieved optimal response at 3, 6, or 12 months than those who achieved non-optimal response (warning or failure), and overall survival rate at 5 years was significantly higher in those who achieved optimal response at 12 months (P =0.047). Achieving optimal response at 12 months was associated with better role limitations due to physical health problems (P =0.0019) and role limitations due to emotional problems (P =0.0110) and was the sole factor associated with significantly improving physical component summary over time (P =0.0160). In addition, achieving optimal response at 6 months had a tendency of high physical functioning (P =0.0674), social functioning (P =0.0571), and role limitations due to emotional problems (P =0.0916) scores. Age <40 years, female gender, and higher education level were also associated with better HRQoL subscales.
Conclusion
Session topic: 8. Chronic myeloid leukemia - Clinical
Keyword(s): Tyrosine kinase inhibitor, Quality of Life, Chronic myeloid leukemia